Hemerion Therapeutics is focused on developing innovative therapies for glioblastoma, a highly aggressive form of brain cancer. The company employs a unique drug-device combination known as Pentalafen® and Heliance®, which is designed to enhance the effectiveness of intraoperative photodynamic therapy (PDT). This approach utilizes light to target and eradicate cancer cells while minimizing damage to surrounding healthy tissue. Hemerion's clinical trials, including the ongoing HTX-GBM-01 study, aim to assess the safety and efficacy of this treatment in patients with newly diagnosed glioblastoma, with promising early results indicating high tolerance and potential for improved patient outcomes.

The company's research has evolved through extensive preclinical and clinical validation, with significant milestones achieved in recent years. Notably, the INDYGO trial demonstrated the feasibility and non-toxicity of Hemerion's technology, leading to further studies like DOSINDYGO, which explores higher doses of light for deeper tumor penetration. The results from these trials have shown encouraging signs of efficacy, with some patients experiencing extended progression-free survival. Hemerion's commitment to advancing cancer therapies is underscored by its ongoing partnerships and recognition for its innovative approach in the field of oncology.

France

Hemerion is a clinical stage HealthTech company. Its first breakthrough technology jointly designed with University of Lille, Inserm and University Hospital of Lille, addresses brain cancer and aims to help patients in their fight against glioblastoma.

Hemerion results of over 10 years of leading academic and clinical researches on innovative approaches to treat Glioblastoma.

Today, Hemerion owns a unique and disruptive technology, already evaluated in frontline approach to treat patients harboring brain cancer.

Hemerion Therapeutics

Company Details